Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 19

1.

One step closer to defining Alzheimer's causes. ApoE4 gene identified as possible target for drug therapy in Alzheimer's treatment.

[No authors listed]

Duke Med Health News. 2012 Aug;18(8):6. No abstract available.

PMID:
23029675
2.

Detrimental effects of apolipoprotein E4: potential therapeutic targets in Alzheimer's disease.

Mahley RW, Huang Y, Weisgraber KH.

Curr Alzheimer Res. 2007 Dec;4(5):537-40. Review.

PMID:
18220516
3.

Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease.

Huang Y.

Trends Mol Med. 2010 Jun;16(6):287-94. doi: 10.1016/j.molmed.2010.04.004. Review.

PMID:
20537952
4.

Apolipoprotein E ε4 prevalence in Alzheimer's disease patients varies across global populations: a systematic literature review and meta-analysis.

Crean S, Ward A, Mercaldi CJ, Collins JM, Cook MN, Baker NL, Arrighi HM.

Dement Geriatr Cogn Disord. 2011;31(1):20-30. doi: 10.1159/000321984. Review.

5.

Pathological synergism between amyloid-beta and apolipoprotein E4--the most prevalent yet understudied genetic risk factor for Alzheimer's disease.

Belinson H, Michaelson DM.

J Alzheimers Dis. 2009;17(3):469-81. doi: 10.3233/JAD-2009-1065. Review.

PMID:
19363257
6.

Molecular and cellular mechanisms of apolipoprotein E4 neurotoxicity and potential therapeutic strategies.

Huang Y.

Curr Opin Drug Discov Devel. 2006 Sep;9(5):627-41. Review.

PMID:
17002223
7.

Apolipoprotein E4 as a target for developing new therapeutics for Alzheimer's disease.

Refolo LM, Fillit HM.

J Mol Neurosci. 2004;23(3):151-5. Review.

PMID:
15181243
8.

Diabetes, Alzheimer's disease and apolipoprotein genotype.

Messier C.

Exp Gerontol. 2003 Sep;38(9):941-6. Review.

PMID:
12954480
9.

Pathogenesis of Alzheimer's disease: current status on apolipoprotein E4 gene research.

Das HK, Lal H.

Rev Neurosci. 1996 Oct-Dec;7(4):277-83. Review.

PMID:
9044502
10.

Alzheimer's disease: clinical implications of the apolipoprotein E genotype.

Farlow MR.

Neurology. 1997 May;48(5 Suppl 6):S30-4. Review.

PMID:
9153158
11.

Alzheimer's disease: epidemiology, genetics, and beyond.

Wang XP, Ding HL.

Neurosci Bull. 2008 Apr;24(2):105-9. doi: 10.1007/s12264-008-0105-7. Review.

PMID:
18369390
12.

Cholesterol and apoe: a target for Alzheimer's disease therapeutics.

Fenili D, McLaurin J.

Curr Drug Targets CNS Neurol Disord. 2005 Oct;4(5):553-67. Review.

PMID:
16266288
13.

Apolipoprotein E polymorphism and susceptibility to Alzheimer's disease.

Kamboh MI.

Hum Biol. 1995 Apr;67(2):195-215. Review.

PMID:
7729825
14.

Alzheimer's disease: treatment research finds new targets.

Hodes RJ.

J Am Geriatr Soc. 1994 Jun;42(6):679-81. Review. No abstract available.

PMID:
8201156
15.

Fatty acids, lipid metabolism and Alzheimer pathology.

Hooijmans CR, Kiliaan AJ.

Eur J Pharmacol. 2008 May 6;585(1):176-96. doi: 10.1016/j.ejphar.2007.11.081. Review.

PMID:
18378224
16.

Genetic heterogeneity of Alzheimer's disease: complexity and advances.

Lambert JC, Amouyel P.

Psychoneuroendocrinology. 2007 Aug;32 Suppl 1:S62-70. Review.

PMID:
17659844
17.

Genetic susceptibility factors for Alzheimer's disease.

Richard F, Amouyel P.

Eur J Pharmacol. 2001 Jan 19;412(1):1-12. Review.

PMID:
11166730
18.

[Modern approaches to the therapy of Alzheimer's disease].

Damulin IV.

Zh Nevrol Psikhiatr Im S S Korsakova. 1998;98(12):56-62. Review. Russian. No abstract available.

PMID:
9866163
19.

Molecular genetic approaches in the therapy of Alzheimer's disease.

Giacobini E.

Adv Exp Med Biol. 1990;265:277-81. Review. No abstract available.

PMID:
2198778
Items per page

Supplemental Content

Support Center